Showing 1021-1030 of 1616 results for "".
- RevolutionEHR Announces Early Access to Redesigned Patient Portalhttps://modernod.com/news/revolutionehr-announces-early-access-to-redesigned-patient-portal/2485693/RevolutionEHR, a cloud-based electronic health record and practice management platform for optometry,
- Novel Imaging Technology Reveals Role of Immune Cells in Early Diabetic Cataract Developmenthttps://modernod.com/news/novel-imaging-technology-reveals-role-of-immune-cells-in-early-diabetic-cataract-development/2481420/Novel findings from researchers contradict previous notions about sugar's role in the onset of diabetic cataracts. The team of researchers, led by Prof. Ali Hafezi-Moghadam, MD, PhD, Director of the Molecular Biomarkers Nano-Imaging Laboratory (MBNI) at the Brigham and Wom
- Ophthalmic World Leaders (OWL) Names First MD President and Other Leadership Changes for 2026https://modernod.com/news/ophthalmic-world-leaders-owl-names-first-md-president-and-other-leadership-changes-for-2026/2484293/Ophthalmic World Leaders (OWL) announces the appointment of Renee Bovelle, MD, as its new President. OWL also welcomes three new members to its Board of Directors: Kevin M. Douglas, MD (Medical Director, Eye Care – Retina, AbbVie), Maáza Martin (S
- Geoff Tabin, MD, Co-Founder of Global NGO HCP Cureblindness, Steps Into New Rolehttps://modernod.com/news/geoff-tabin-md-co-founder-of-global-ngo-hcp-cureblindness-steps-into-new-role/2482314/Effective immediately, Geoff Tabin, MD, will step down as Board Chair of the global nonprofit HCP Cureblindness (Himalayan Cataract Project), but will maintain an active role on the Board as Medical Director. Long-time HCP volunteer and Board Member, Matt Oliva, MD, will lead HCP into its excitin
- Azura Ophthalmics Enrolls First Patient in Phase 3 Clinical Trial for AZR-MD-001 in Patients with MGDhttps://modernod.com/news/azura-ophthalmics-enrolls-first-patient-in-phase-3-clinical-trial-for-azr-md-001-in-patients-with-mgd/2482307/Azura Ophthalmics announced that the first patient has been enrolled in the ASTRO study—a phase 3 clinical trial assessing the efficacy and safety of AZR-MD-001 in patients with clinical signs and symptoms of meibomian gland dysfunction (MGD). "AZR-MD-001 has already dem
- Centre for Sight Launches 'Eye Health MOT' to Support Early Detection and Long-Term Vision Carehttps://modernod.com/news/centre-for-sight-launches-eye-health-mot-to-support-early-detection-and-long-term-vision-care/2485486/Centre for Sight has launched a new 'Eye Health MOT' service for people aged 40 and over, designed to offer a comprehensive, consultant-led assessment to detect early signs of eye disease before symptoms appear. According to C
- Alkeus Announces Interim TEASE-3 Study Results Evaluating Gildeuretinol in Early-Stage Stargardt Patientshttps://modernod.com/news/alkeus-announces-new-interim-tease-3-study-results-showing-gildeuretinol-prevented-disease-progression-in-early-stage-stargardt-patients/2482608/Alkeus Pharmaceuticals announced positive interim data from its TEASE-3 study demonstrating that additional early-stage Stargardt disease patients treated with oral gildeuretinol acetate showed no disease progression, including stable visual acuity, over multiple years. “Thes
- Zeiss and Boehringer Ingelheim Partner to Develop Early Detection of Eye Diseases and Prevent Vision Losshttps://modernod.com/news/zeiss-and-boehringer-ingelheim-partner-to-develop-early-detection-of-eye-diseases-and-prevent-vision-loss/2481859/Zeiss Medical Technology and Boehringer Ingelheim announced a long-term strategic collaboration to develop predictive analytics to enable early detection of eye diseases and more personalized treatments to prevent vision loss for people with eye diseases. The partnership aims to bring togeth
- Study: Early Anti-VEGF Treatment of Diabetic Retinopathy Slows Progression but Yields No Benefit to Visual Acuityhttps://modernod.com/news/study-early-anti-vegf-treatment-of-diabetic-retinopathy-slows-progression-but-yields-no-benefit-to-visual-acuity/2481399/While early treatment of diabetes-related eye disease slowed progression to severe disease, it did not improve visual acuity compared with treating more severe disease once it developed, according to a clinical study from the DRCR Retina Network. The study was funded by the National Eye Institute
- Aura Biosciences Reports Data from Study of Belzupacap Sarotalocan Versus Plaque Radiotherapy for Early-Stage Choroidal Melanomahttps://modernod.com/news/aura-biosciences-reports-topline-data-from-a-retrospective-study-of-belzupacap-sarotalocan-versus-plaque-radiotherapy-for-the-treatment-of-patients-with-early-stage-choroidal-melanoma/2480928/Aura Biosciences reported results from a retrospective, matched case control study that assessed the visual acuity of patients following treatment with plaque radiotherapy compared with prospective data on visual acuity in subjects with early-stage choroidal melanoma treated with belzup